Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The FDA has granted Orphan Drug Designation to BioInvent International AB's (OTC:BOVNF) BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- BioInvent is a collaborating partner of CASI Pharmaceuticals Inc (NASDAQ:CASI).
- BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials.
- One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have relapsed or are refractory to rituximab.
- A second Phase 1/2 trial is investigating BI-1206 in combination with Merck & Co Inc (NYSE:MRK) anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.
- Price Action: CASI shares are up 4.21% at $0.72 during the premarket session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.